Armata Pharmaceuticals, Inc. ARMP
3.74
0.12
3.31%
as of 25 Sep
- Market cap
- $136.5M
- P/E
- 0.0×
Follow ARMP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
64.00% | 130.37% | 154.70% | 127.83% | |
| (49.96%) | (212.83%) | (359.90%) | (225.11%) | ||
ROIC |
(57.94%) | (77.26%) | (87.61%) | (89.61%) | |
Return on Tangible Assets |
42.46% | (1,249.00%) | (3,325.65%) | 90.73% | |
Average Days of Receivables |
54.82 | 35.13 | 3.30 | 166.73 | |
Free Cash Flow per Share |
(0.76) | (0.73) | (0.67) | (0.70) | |
Free Cash Flow |
(27.43) | (26.30) | (24.47) | (25.79) | |
Capital Expenditures |
(0.41) | (0.54) | (0.51) | (0.37) | |
Piotroski F-Score |
1.00 | 2.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(41.25%) | (54.80%) | (66.45%) | (33.32%) | |
Accounts Receivable Turnover |
3.39 | 8.07 | 36.51 | 2.36 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
516.36% | 483.63% | 469.03% | 461.68% | |
Selling, General and Administrative Expense of Revenue |
243.49% | 253.04% | 242.58% | 274.87% | |
Share Based Compensation of Revenue |
46.14% | 53.22% | 55.82% | 103.19% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.58 | 0.15 | 0.08 | 0.13 | |
Depreciation/Fixed assets |
0.12 | 0.13 | 0.14 | 0.16 | |
Capex/Depreciation |
(0.28) | (0.35) | (0.31) | (0.20) | |
Revenue per Share |
0.14 | 0.14 | 0.14 | 0.15 | |
Operating CF per Share |
(0.75) | (0.71) | (0.66) | (0.69) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.08 | 0.11 | 0.10 | 0.07 | |
Net Profit Margin |
(928.00%) | (3,544.03%) | (5,432.80%) | (3,467.04%) |
Columns are period end dates